WEBINAR VIDEO | IP UPDATE #4: TRADE SECRETS – BE AWARE AND BE PAREPARED
During our fourth online IP Update, you will learn more about trade secrets and how your company can take care of its sensitive information. Presenters Sophie Lens and Hans Verstrepen will answer questions such as:
- What is a trade secret?
- How does a trade secret differ from an intellectual property right and why choose one over the other?
- What measures should a company implement to best protect its trade secrets?
- What measures are available in the event of a breach and how can you ensure that the secret is not further disclosed in the course of the legal proceedings aimed at protecting it?
Are parallel importers necessarily allowed to rebox medicines in case of visible traces from ATDs? The CJEU says NO
Pharmaceutical companies are obliged to affix an anti-tampering device (‘ATD’) on prescription-only medicines to enable verification of whether a medicine’s packaging has been tampered with. Parallel importers argue that this results in an overarching objective necessity to ‘rebox’ such medicines.Read on
If a branded medicine and its generic version are put on the EEA market by economically-linked undertakings, is a parallel importer then allowed to rebrand and repackage the imported generic version as the branded reference medicine? After the Brussels Court of Appeal had referred questions on this issue for a preliminary ruling two years ago, the CJEU has now clarified the limits.Read on
Copyright fit for the internet age? Belgium implements the DSM directive (Part 3: New rules governing copyright contracts)
On 1 August 2022, the Belgian law transposing the Directive on Copyright in the Digital Single Market (“DSM directive”) (EU Directive 2019/790) was published in the Belgian State Gazette (NL / FR). The new law enters into effect immediately (with the exception of a few provisions).Read on